Welcome to NGC. Skip directly to: Search Box, Navigation, Content.


Brief Summary

GUIDELINE TITLE

Guidelines for the field management of combat-related head trauma. Treatment: pain management and the use of analgesics for sedation.

BIBLIOGRAPHIC SOURCE(S)

  • Knuth T, Letarte PB, Ling G, Moores LE, Rhee P, Tauber D, Trask A. Guidelines for the field management of combat-related head trauma. Treatment: pain management and the use of analgesics for sedation. New York (NY): Brain Trauma Foundation; 2005. 8 p. [23 references]

GUIDELINE STATUS

This is the current release of the guideline.

BRIEF SUMMARY CONTENT

 
RECOMMENDATIONS
 EVIDENCE SUPPORTING THE RECOMMENDATIONS
 IDENTIFYING INFORMATION AND AVAILABILITY
 DISCLAIMER

 Go to the Complete Summary

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

"Degrees of Certainty" (Standards, Guideline, Options) and "Classification of Evidence" (Class I to III) and the correlation between the two are defined at the end of the "Major Recommendations" field.

Recommendations

  1. Standards

    Class I data regarding management of pain in the prehospital setting is insufficient to support a standard of treatment.

  2. Guidelines

    Evidence regarding management of pain in the prehospital setting does not exist to support guidelines on this topic.

  3. Options
    1. There are valid reasons to sedate traumatic brain injury (TBI) patients (i.e. to reduce the risk of further harm to self or others and to facilitate evaluation or evacuation) and analgesic medications are a standard part of most sedative regimens. In this case, analgesic medications should be administered in small incremental doses and with appropriate physiologic monitoring of blood pressure, oxygenation (arterial partial oxygen pressure or arterial blood oxygen saturation [PaO2 or SaO2]), and ventilation (carbon dioxide partial pressure or end-tidal carbon dioxide [pCO2 or EtCO2]).
    2. There is no scientific data or physiologic evidence to support a hypothesis that pain relief improves outcomes in TBI patients, but there is some evidence to support the possibility that the most commonly available analgesic medications (including opiates and Ketamine) increase intracranial pressure (ICP) and may thereby be harmful. Therefore, withholding analgesics from TBI patients who cannot self-score pain (Glasgow Coma Scale score [GCS] <13; see the National Guideline Clearinghouse [NGC] summary of the Brain Trauma Foundation [BTF] Guidelines for the field management of combat-related head trauma. Assessment: Glasgow Coma Scale scoring and assessment of pupils) for short periods in the prehospital phase, where monitoring is unavailable, is a reasonable option.

Summary

There may be valid reasons for wanting to control pain in the prehospital setting if it contributes to anxiety or to harmful activity but there is simply no evidence to indicate whether this is helpful or harmful in this setting. The Hippocratic Rule to "First Do No Harm" should therefore guide commonplace practice. Cautious discriminate use with as much physiologic monitoring as possible is advised.

Pain management for TBI patients in the prehospital setting should be guided by the following principles:

  1. In the case of a minor closed head injury (GCS 13–15), a subjective assessment scale should be used before administering any analgesic and again before each additional dose. The goal should be to reduce pain to a level so that the patient remains comfortable but is not obtunded by the medication.
  2. In addition to effective pain relief, the ideal analgesic must not alter vital signs, hide complications, or cause delay in therapeutic decision-making.
  3. Analgesics should always be administered in small incremental doses.
  4. Monitoring should not be limited to intermittent manual observation; the paramedic must be able to use, interpret, and act upon the data derived from patient assessment and monitoring technology to help ensure a positive outcome for the patient.
  5. Hypotension (systolic blood pressure [SBP] <90 mm Hg) must be avoided or corrected immediately by administering IV fluids. SBP should be monitored as frequently as possible or continuously. (See NGC summary of the BTF Guidelines for the field management of combat-related head trauma. Treatment: fluid resuscitation).
  6. Oxygen saturation should be monitored as frequently as possible or continuously. Hypoxemia (apnea, cyanosis, or oxygen saturation [SaO2] <90%) must be avoided, if possible, or corrected immediately by administering supplemental oxygen. (See the NGC summary of the BTF Guidelines for the field management of combat-related head trauma. Treatment: airway, ventilation, and oxygenation).
  7. End-tidal carbon dioxide (EtCO2) should be monitored as frequently as possible or continuously. Hypocapnea with hypercarbia (respiratory depression with rise in EtCO2) causes cerebral vasodilatation and subsequent increased intracranial pressure that must be avoided, if possible, or corrected immediately by administering small incremental doses of Narcan or by assisting ventilation with a bag-valve-mask device or by intubating and placing the patient on a ventilator. (See the NGC summary of the BTF Guidelines for the field management of combat-related head trauma. Treatment: airway, ventilation, and oxygenation).

Definitions:

Classes of Evidence

Class I: Evidence from good quality randomized controlled trials (RCT)

Class II: Evidence from moderate or poor quality RCT, good quality cohort, or good quality case-control studies

Class III: Evidence from moderate or poor quality cohort; or moderate or poor quality case-control; or case series, databases, or registries

Degrees of Certainty

Standards: Reflect a high degree of clinical certainty as indicated by the scientific evidence available (supported by Class I evidence).

Guidelines: Reflect a moderate degree of clinical certainty as indicated by the scientific evidence available (supported by Class II evidence).

Options: Reflect unclear clinical certainty as indicated by the scientific evidence available (supported by Class III evidence).

CLINICAL ALGORITHM(S)

A clinical algorithm for "Field Management of Combat-Related Head Trauma" is provided in the original guideline document.

EVIDENCE SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

An evidentiary table appears at the end of each major section of the guideline document, which classifies each citation based on the quality of the evidence (Class I-III; see "Major Recommendations" for definitions). The recommendations in this summary are supported by six Class III studies and one Class II study.

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

  • Knuth T, Letarte PB, Ling G, Moores LE, Rhee P, Tauber D, Trask A. Guidelines for the field management of combat-related head trauma. Treatment: pain management and the use of analgesics for sedation. New York (NY): Brain Trauma Foundation; 2005. 8 p. [23 references]

ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

2005

GUIDELINE DEVELOPER(S)

Brain Trauma Foundation - Disease Specific Society

SOURCE(S) OF FUNDING

Brain Trauma Foundation

Uniformed Services University of the Health Sciences

GUIDELINE COMMITTEE

Not stated

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Authors: Tom Knuth, MD, MPH, FACS, COL, Medical Corps, US Army, Chief, Combat Casualty Care Integrated Concepts Team, Directorate of Combat Doctrine and Development, Army Medical Department Center and School, Fort Sam Houston, Texas; Peter B. Letarte, MD, FACS, Neurosurgeon, Hines VA Medical Center, Loyola University Medical Center; Geoffrey Ling, MD, PhD, LTC, Medical Corps, US Army, Professor and Vice-Chair of Neurology, Director of Critical Care Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland; Leon E. Moores, MD, FACS, LTC, Medical Corps, US Army, Assistant Professor of Surgery and Pediatrics, Uniformed Services University of the Health Sciences, Chief of Neurosurgery, Director of Pediatric Neurological Surgery, Walter Reed Army Medical Center; Peter Rhee, MD, MPH, FACS, FCCM, CAPT, Medical Corps, US Navy, Professor of Surgery/Molecular Cellular Biology, Director, Navy Trauma Training Center, Los Angeles County Medical Center, University of Southern California; David Tauber, CCEMT-P, NREMT-P, I\C, Executive Director, Advanced Life Support Institute (New Hampshire) Medical Specialist/Hazardous Materials Technician, FEMA USAR Team MA1; Art Trask, MD, FACS, INOVA Regional Trauma Center, INOVA Fairfax Hospital

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Not stated

GUIDELINE STATUS

This is the current release of the guideline.

GUIDELINE AVAILABILITY

Electronic copies: Available in Portable Document Format (PDF) from the Brain Trauma Foundation Web site.

Print copies: Available from the Brain Trauma Foundation, 708 Third Avenue, New York, NY 10017

AVAILABILITY OF COMPANION DOCUMENTS

None available

PATIENT RESOURCES

None available

NGC STATUS

This NGC summary was completed by ECRI Institute on August 24, 2007. The information was verified by the guideline developer on January 28, 2008.

COPYRIGHT STATEMENT

This is a limited license granted to NGC, AHRQ and its agent only. It may not be assigned, sold, or otherwise transferred. BTF owns the copyright. For any other permission regarding the use of these guidelines, please contact the Brain Trauma Foundation.

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at http://www.guideline.gov/about/inclusion.aspx .

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.


 

 

   
DHHS Logo